Kelly Broster

This article explores the key challenges analytics and mass spectrometry solve within the biopharmaceutical industry.

This instalment of “Perspectives in Modern HPLC” provides an overview of antibody–drug conjugates (ADCs) as a new class of biotherapeutics and describes their analytical characterization for quality assessment with examples from extensive applications libraries.

Comprehensive characterization of ADCs requires increasingly powerful approaches consisting of small- and large-molecule techniques.